Breaking News Headlines Today | Ground News

See every side of every news story

Gilead Sciences image

News about Gilead Sciences

Stay current with all the latest and breaking news about Gilead Sciences, compare headlines and perspectives between news sources on stories happening today. In total, 42stories have been published about Gilead Sciences which Ground News has aggregated in the past 3 months.

Covered Most By

GeneOnline News

Suggest a source

Local News Publishers

Suggest a source

Looking for a source we don't already have? Suggest one here.

Top Gilead Sciences News

Bill Gates Says Trump's Cuts to USAID Are Devastating: 'It’s Not Too Late to Reverse Them'

Donald Trump · United States

Bill Gates Says Trump's Cuts to USAID Are Devastating: 'It’s Not Too Late to Reverse Them'

34% Center coverage: 9 sources

Gates is reacting to Trump's cutbacks affecting a longtime partner of the nonprofit Gates Foundation.See the Story

HIV Drug Manufacturing Company Owes Big Money in Kickback Settlement Case

Gilead Sciences

HIV Drug Manufacturing Company Owes Big Money in Kickback Settlement Case

57% Center coverage: 7 sources

A major HIV drug maker will return $202 million nationwide after a multi-year investigation and settlement.See the Story

New WHO Guidelines Recommend Injectable Lenacapavir for HIV Prevention

World Health Organization

New WHO Guidelines Recommend Injectable Lenacapavir for HIV Prevention

60% Center coverage: 5 sources

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice a year as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention, in a landmark policy action that could help reshape the global HIV response.See the Story

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.

100% Left coverage: 1 sources

Open the article to view the coverage from Kilgore News HeraldGilead Sciences See the Story

Q2 EPS Estimates for Gilead Sciences Reduced by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Investment analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for shares of Gilead Sciences in a research report issued to clients and investors on Monday, July 14th. Leerink Partnrs analyst D. Graybosch now anticipates that the biopharmaceutical company will post earnings per share of $1.91 […]Gilead Sciences · Foster City Read Article

ViiV Healthcare Presents New Data Demonstrating Positive Real-World Impact of Its Innovative Long-Acting Injectables for HIV at IAS 2025

100% Left coverage: 1 sources

LONDON--(BUSINESS WIRE)--Jul 8, 2025-FDA See the Story

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today - Gilead Sciences (NASDAQ:GILD)

100% Center coverage: 1 sources

Gilead Sciences Read Article

$100 Invested In First BanCorp 15 Years Ago Would Be Worth This Much Today - First BanCorp (NYSE:FBP)

100% Center coverage: 1 sources

First BanCorp (NYSE:FBP) has outperformed the market over the past 15 years by 15.29% on an annualized basis producing an average annual return of 27.71%. Currently, First BanCorp has a market capitalization of $3.54 billion. Buying $100 In FBP: If ... Full story available on Benzinga.comFinance · San Juan See the Story

Only Two Shots a Year: First HIV Vaccine Gets FDA Approval

A milestone in preventing HIV, now available with each injection being good for 6 months each… Photo from Unsplash Yeztugo is the brand name for lenacapavir, a long acting injectable developed by Gilead Sciences. It is the first and only FDA approved HIV prevention option that requires two injections per year. This works by inhibiting the HIV capsid, a protein shell essential for viral replication that is blocking the virus at multiple stages of…Gilead Sciences · Cebu Read Article

Gilead Sciences: A Mixed Bag of Opportunities and Risks @themotleyfool #stocks $GILD

100% Left coverage: 1 sources

Gilead Sciences · Foster City Read Article

FDA Loosens Restrictions on First-Gen CAR-T Therapies

100% Center coverage: 2 sources

There is enough experience with the first wave of autologous CAR-T therapies to allow strict rules ensuring their safe use to be relaxed, says FDA.Cancer · United States See the Story

Breaking News Topics Related to Gilead Sciences